CF 101 (known generically as IB-MECA) is an anti-inflammatory drug for rheumatoid arthritis patients. Its novel mechanism of action relies on antagonism of adenoside A3 receptors. CF101 is supplied as... CF101 is supplied as an oral drug and has an excellent safety profile.
- Mechanism
- Curator reviewed
CF 101 is an A(3)AR agonist. A(3)AR is highly expressed in inflammatory cells and overexpressed in peripheral blood mononuclear cells, reflecting its role in the remote inflammatory process. In normal tissues, there is low adenoside A3 receptor expression. A(3)AR activation with a specific agonist deregulates the NF-kappaB signaling pathway in inflammatory cells and initiates immunomodulatory effects.
- Primary indication
- Investigated for use/treatment in cancer/tumors (unspecified), eye disorders/infections, psoriasis and psoriatic disorders, and rheumatoid arthritis.Curator reviewed
- Formula / weight
- C18H19IN6O4 · 510.2857 g/mol (avg)
- Code names
- CF-101 · IB-MECA
Resolves to
HUJXGQILHAUCCV-MOROJQBDSA-NSMILESCNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=NC2=C(NCC3=CC(I)=CC=C3)N=CN=C12What you can answer from here — as of June 15, 2026
Which drugs share a target with Piclidenoson, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account